FY2017 EPS Estimates for Chimerix, Inc. (CMRX) Raised by Analyst
Chimerix, Inc. (NASDAQ:CMRX) – Stock analysts at William Blair upped their FY2017 earnings per share estimates for Chimerix in a research note issued to investors on Wednesday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings of ($1.56) per share for the year, up from their previous forecast of ($1.70). William Blair also issued estimates for Chimerix’s Q4 2017 earnings at ($0.43) EPS, FY2018 earnings at ($1.84) EPS and FY2019 earnings at ($1.90) EPS.
Several other brokerages also recently commented on CMRX. ValuEngine raised Chimerix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 11th. Zacks Investment Research raised Chimerix from a “sell” rating to a “hold” rating in a research note on Monday, July 17th.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/fy2017-eps-estimates-for-chimerix-inc-cmrx-raised-by-analyst/1697108.html.
Chimerix (CMRX) opened at $4.90 on Friday. Chimerix has a 52 week low of $4.28 and a 52 week high of $6.64.
Chimerix (NASDAQ:CMRX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%.
Hedge funds and other institutional investors have recently modified their holdings of the business. Metropolitan Life Insurance Co. NY acquired a new position in Chimerix during the first quarter worth about $226,000. Dimensional Fund Advisors LP increased its stake in shares of Chimerix by 114.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after buying an additional 557,927 shares during the period. Geode Capital Management LLC increased its stake in shares of Chimerix by 11.7% in the first quarter. Geode Capital Management LLC now owns 341,238 shares of the biopharmaceutical company’s stock valued at $2,177,000 after buying an additional 35,752 shares during the period. AXA increased its stake in shares of Chimerix by 284.9% in the second quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock valued at $1,409,000 after buying an additional 191,400 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Chimerix by 7.0% in the first quarter. Bank of New York Mellon Corp now owns 245,080 shares of the biopharmaceutical company’s stock valued at $1,564,000 after buying an additional 16,117 shares during the period. 67.56% of the stock is owned by hedge funds and other institutional investors.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.